Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Jan;135(1):25-7.
doi: 10.1038/sj.bjp.0704448.

Urotensin II evokes potent vasoconstriction in humans in vivo

Felix Böhm  1 , John Pernow
Affiliations
Clinical Trial

Urotensin II evokes potent vasoconstriction in humans in vivo

Felix Böhm et al. Br J Pharmacol. 2002 Jan.

Abstract

The peptide urotensin II (U II) evokes potent vasoconstriction in non-human primates. In human blood vessels studied in vitro variable effects of U II are reported; vasoconstriction, vasodilatation or no response. It is therefore of importance to determine the vascular effect of U II in humans in vivo. U II (0.1 - 300 pmol min(-1)) was infused into the brachial artery of nine healthy volunteers. Changes in forearm blood flow (FBF) were determined by venous occlusion plethysmography. U II induced dose-dependent reduction in FBF. A threshold response was obtained by 1 pmol min(-1), and the highest dose of U II (300 pmol min(-1)) reduced FBF by 31+/-4% (P<0.01). FBF returned to baseline values within 30 min. This study demonstrates that U II produces potent vasoconstriction in humans in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of urotensin II on forearm blood flow. Values are expressed (A) as per cent change in flow and (B) in absolute blood flow. Data are given as mean values and s.e.means (n=9). Significant differences from pre-infusion values (Time 0) are shown; *P<0.05, **P<0.01.
See this image and copyright information in PMC

References

    1. AMES R.S., SARAU H.M., CHAMBERS J.K., WILLETTE R.N., AIYAR N.V., ROMANIC A.M., LOUDEN C.S., FOLEY J.J., SAUERMELCH C.F., COATNEY R.W., AO Z., DISA J., HOLMES S.D., STADEL J.M., MARTIN J.D., LIU W.S., GLOVER G.I., WILSON S., MCNULTY D.E., ELLIS C.E., ELSHOURBAGY N.A., SHABON U., TRILL J.J., HAY D.W., DOUGLAS S.A. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282–286. - PubMed
    1. BOTTRILL F.E., DOUGLAS S.A., HILEY C.R., WHITE R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol. 2000;130:1865–1870. - PMC - PubMed
    1. COULOUARN Y., LIHRMANN I., JEGOU S., ANOUAR Y., TOSTIVINT H., BEAUVILLAIN J.C., CONLON J.M., BERN H.A., VAUDRY H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U.S.A. 1998;95:15803–15808. - PMC - PubMed
    1. GARDINER S.M., MARCH J.E., KEMP P.A., DAVENPORT A.P., BENNETT T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br. J. Pharmacol. 2001;132:1625–1629. - PMC - PubMed
    1. HILLIER C., BERRY C., PETRIE M.C., O'DWYER P.J., HAMILTON C., BROWN A., MCMURRAY J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation. 2001;103:1378–1381. - PubMed

Publication types

MeSH terms

LinkOut - more resources